Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Intercept Pharmaceuticals stock | 37.55

Own Intercept Pharmaceuticals stock in just a few minutes.


Fact checked

Intercept Pharmaceuticals, Inc is a biotechnology business based in the US. Intercept Pharmaceuticals shares (ICPT) are listed on the NASDAQ and all prices are listed in US Dollars. Intercept Pharmaceuticals employs 583 staff and has a trailing 12-month revenue of around USD$283.4 million.

How to buy shares in Intercept Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Intercept Pharmaceuticals. Find the stock by name or ticker symbol: ICPT. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Intercept Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$37.55, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Intercept Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Intercept Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Intercept Pharmaceuticals's share price?

Since the stock market crash in March caused by coronavirus, Intercept Pharmaceuticals's share price has had significant negative movement.

Its last market close was USD$37.55, which is 60.47% down on its pre-crash value of USD$94.99 and 26.68% down on the lowest point reached during the March crash when the shares fell as low as USD$47.57.

If you had bought USD$1,000 worth of Intercept Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$588.30 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$402.16.

Intercept Pharmaceuticals share price

Use our graph to track the performance of ICPT stocks over time.

Intercept Pharmaceuticals shares at a glance

Information last updated 2020-10-19.
Latest market close USD$37.55
52-week range USD$32.15 - USD$125
50-day moving average USD$41.1176
200-day moving average USD$59.4416
Wall St. target price USD$67.32
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-10.436

Buy Intercept Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Intercept Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Intercept Pharmaceuticals price performance over time

Historical closes compared with the close of $37.55 from 2020-11-16

1 week (2020-11-18) 0.51%
1 month (2020-10-26) 30.20%
3 months (2020-08-25) -24.95%
6 months (2020-05-22) -53.36%
1 year (2019-11-25) -61.02%
2 years (2018-11-23) -66.19%
3 years (2017-11-24) -40.59%
5 years (2015-11-25) -79.56%

Intercept Pharmaceuticals financials

Revenue TTM USD$283.4 million
Gross profit TTM USD$247.8 million
Return on assets TTM -25.19%
Return on equity TTM -703.8%
Profit margin -119.73%
Book value $1.569
Market capitalisation USD$1.1 billion

TTM: trailing 12 months

Shorting Intercept Pharmaceuticals shares

There are currently 6.4 million Intercept Pharmaceuticals shares held short by investors – that's known as Intercept Pharmaceuticals's "short interest". This figure is 16.2% up from 5.5 million last month.

There are a few different ways that this level of interest in shorting Intercept Pharmaceuticals shares can be evaluated.

Intercept Pharmaceuticals's "short interest ratio" (SIR)

Intercept Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Intercept Pharmaceuticals shares currently shorted divided by the average quantity of Intercept Pharmaceuticals shares traded daily (recently around 649532.08502024). Intercept Pharmaceuticals's SIR currently stands at 9.88. In other words for every 100,000 Intercept Pharmaceuticals shares traded daily on the market, roughly 9880 shares are currently held short.

However Intercept Pharmaceuticals's short interest can also be evaluated against the total number of Intercept Pharmaceuticals shares, or, against the total number of tradable Intercept Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Intercept Pharmaceuticals's short interest could be expressed as 0.19% of the outstanding shares (for every 100,000 Intercept Pharmaceuticals shares in existence, roughly 190 shares are currently held short) or 0.3085% of the tradable shares (for every 100,000 tradable Intercept Pharmaceuticals shares, roughly 309 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Intercept Pharmaceuticals.

Find out more about how you can short Intercept Pharmaceuticals stock.

Intercept Pharmaceuticals share dividends

We're not expecting Intercept Pharmaceuticals to pay a dividend over the next 12 months.

Intercept Pharmaceuticals share price volatility

Over the last 12 months, Intercept Pharmaceuticals's shares have ranged in value from as little as $32.15 up to $125. A popular way to gauge a stock's volatility is its "beta".

ICPT.US volatility(beta: 1.63)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intercept Pharmaceuticals's is 1.6315. This would suggest that Intercept Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Intercept Pharmaceuticals overview

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinical development. It has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China; and Aralez Pharmaceuticals Canada Inc to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site